BioCentury
ARTICLE | Company News

MedImmune Inc., VasGene deal

September 12, 2005 7:00 AM UTC

MEDI and VasGene partnered to develop VasGene's preclinical MAbs targeting Eph receptor B4 (EphB4) and its ligand, Ephrin B2 (Efnb2), to treat cancer. MEDI is responsible for clinical development an...